Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

v3.21.2
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model

Under the 2019 Plan, the fair value of the Baudax Bio options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions:

 

 

 

 

June 30,

 

 

 

2021

 

 

2020

 

Expected option life

 

5.5 years

 

 

6 years

 

Expected volatility

 

75.37%

 

 

73.75%

 

Risk-free interest rate

 

0.78%

 

 

0.42%

 

Expected dividend yield

 

 

—

 

 

 

—

 
Summary of Stock Option Activity

The following table summarizes Baudax Bio stock option activity during the six months ended June 30, 2021:

 

 

 

Number of
shares

 

 

Weighted
average
exercise
price

 

 

Weighted
average
remaining
contractual life

Balance, December 31, 2020

 

 

2,284,298

 

 

$

3.10

 

 

9.1 years

Granted

 

 

1,494,875

 

 

$

1.26

 

 

 

Expired/forfeited/cancelled

 

 

(333,664

)

 

$

1.71

 

 

 

Balance, June 30, 2021

 

 

3,445,509

 

 

$

2.44

 

 

8.5 years

Vested

 

 

1,161,356

 

 

$

2.87

 

 

7.4 years

Vested and expected to vest

 

 

3,445,509

 

 

$

2.44

 

 

8.5 years
Summary of RSUs Activity

The following table summarizes Baudax Bio RSUs activity during the six months ended June 30, 2021:

 

 

 

Number of
shares

 

Balance, December 31, 2020

 

 

991,012

 

Granted

 

 

603,758

 

Vested and settled

 

 

(338,741

)

Expired/forfeited/cancelled

 

 

(101,803

)

Balance, June 30, 2021

 

 

1,154,226

 

Expected to vest

 

 

1,154,226